Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia.

Presence of a DNMT3A mutation was significantly associated with achievement of CR ( P = 0.045); accordingly, patients with co-mutations in genes in the DNA methylation functional category showed a trend toward attainment of CR ( P = 0.07) ( Fig. 2 ).

also in 53,322 other papers